Last reviewed · How we verify
Ibritumomab Tiuxetan + Maintenance
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells.
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Follicular lymphoma (maintenance therapy).
At a glance
| Generic name | Ibritumomab Tiuxetan + Maintenance |
|---|---|
| Also known as | Ibritumomab Tiuxetan |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Radiolabeled monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ibritumomab tiuxetan binds to the CD20 antigen expressed on B-cell lymphomas, and the tiuxetan chelator carries yttrium-90, a beta-emitting radioisotope that delivers localized radiation to tumor cells and surrounding tissue. The maintenance phase extends therapeutic benefit through repeated or continued dosing to sustain disease control.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- Follicular lymphoma (maintenance therapy)
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Infusion reactions
- Fatigue
- Nausea
Key clinical trials
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (PHASE2)
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma (PHASE4)
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma (PHASE3)
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma (PHASE2)
- Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) (PHASE3)
- Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (PHASE2)
- ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: